|
|
TCRT-PGEN Fundamental & Technical Discussion Board
|
|
||
Safety, persistence of transposed TCells and a documented ORR non virallyShould be sufficient to provide non dilutive financing one would think. As always its the chicken/egg terms conundrum. Are they rejecting lowball bids or are funders waiting to squeeze even better terms or is nobody bidding? The tumor shrinking ,safe,cell persisting $0.50 proposition. Looks like a skewed risk reward at that price. GLTAL |
return to message board, top of board |